TherapeuticsMD, Inc. - TXMD STOCK NEWS

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced an underwritten public offering of approximately 59.5 million shares at a gross proceeds of $110 million, closing expected around February 16, 2021. Cantor Fitzgerald & Co. is the bookrunning manager, with a 30-day option for the underwriter to purchase an additional 8.9 million shares. Proceeds will be used for commercialization of FDA-approved products like IMVEXXY®, BIJUVA®, and ANNOVERA®, along with debt discharge and working capital.

TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, allowing the underwriter a 30-day option to purchase an additional 15% of offered shares. All shares will be sold by the company, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. Proceeds from the offering are intended for commercialization of three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®, as well as to reduce existing debt and general corporate purposes.

TherapeuticsMD, Inc. (NASDAQ: TXMD) will participate in two upcoming investor conferences: the H.C. Wainwright BioConnect Conference from January 11-14, 2021, and the J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 8:20 a.m. Eastern time. Presentations will be available online during the events. TherapeuticsMD specializes in women’s healthcare, focusing on products for family planning, reproductive health, and menopause management. For more details, visit therapeuticsmd.com.

TherapeuticsMD (NASDAQ:TXMD) has launched Just Say Vagina, a campaign aimed at empowering women to openly discuss reproductive health issues. Comedian Whitney Cummings, who has utilized the ANNOVERA® contraceptive, will be featured, encouraging women to abandon euphemisms in favor of direct communication about their needs. The press release highlights that 45% of unintended pregnancies in the U.S. stem from inconsistent contraceptive use, and 47% of women discontinue birth control due to dissatisfaction.

TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed an underwritten public offering of 23,437,500 shares of its common stock, generating net proceeds of approximately $27.5 million after deducting underwriting discounts and commissions. All shares were sold by TherapeuticsMD, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. The offering was conducted under a previously declared effective shelf registration statement with the SEC.

TherapeuticsMD, Inc. (NASDAQ: TXMD) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 a.m. Eastern time. Investors can access a live webcast of the presentation on the company’s website. TherapeuticsMD focuses on developing innovative products for women's healthcare, addressing issues in family planning, reproductive health, and menopause management. The company aims to enhance women’s health and raise awareness of their healthcare challenges.

TherapeuticsMD (NASDAQ:TXMD) announced the pricing of its public offering of approximately 23.4 million shares, aiming for gross proceeds of $30 million. The offering is set to close around November 12, 2020, pending customary conditions. A 30-day option for underwriters to purchase an additional 3.5 million shares is also granted. The proceeds will fund the commercialization of three FDA-approved products: IMVEXXY, BIJUVA, and ANNOVERA, as well as working capital and general corporate purposes.

TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, granting the underwriter a 30-day option to purchase an additional 15% of shares. The proceeds will primarily be used for the commercialization of its three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®. Funds will also support working capital and general corporate purposes. Cantor Fitzgerald & Co. is the sole bookrunning manager for this offering.

TherapeuticsMD, Inc. (NASDAQ:TXMD) reported a significant 80% increase in net revenue to $19.3 million for Q3 2020, surpassing estimates for the sixth consecutive quarter. This growth was driven by a 62% rise in product sales to $17.3 million. The company reduced operating expenses by $11.0 million, totaling $37.1 million. Notably, ANNOVERA revenue soared by 250% to $6.4 million, while IMVEXXY and BIJUVA also showed strong performance. The company is exploring the divestiture of vitaCare, potentially unlocking over $50 million in non-dilutive proceeds for shareholders.